Porton Pharma Solutions (SZSE:300363) 3-Year EBITDA Growth Rate : 7.00% (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Porton Pharma Solutions 3-Year EBITDA Growth Rate?

Porton Pharma Solutions's EBITDA per Share for the three months ended in Mar. 2024 was ¥-0.23.

During the past 12 months, Porton Pharma Solutions's average EBITDA Per Share Growth Rate was -107.20% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was 7.00% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 29.50% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 17.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Porton Pharma Solutions was 91.30% per year. The lowest was -4.10% per year. And the median was 14.80% per year.

Competitive Comparison of Porton Pharma Solutions's 3-Year EBITDA Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Porton Pharma Solutions's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Porton Pharma Solutions's 3-Year EBITDA Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Porton Pharma Solutions's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Porton Pharma Solutions's 3-Year EBITDA Growth Rate falls into.

Porton Pharma Solutions 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Porton Pharma Solutions (SZSE:300363) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Porton Pharma Solutions 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Porton Pharma Solutions's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Porton Pharma Solutions (SZSE:300363) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Porton Pharma Solutions Ltd (SZSE:300363) » Definitions » 3-Year EBITDA Growth Rate

Traded in Other Exchanges

N/A

Address

Fangzheng Avenue, Porton New Drug Outsourcing Service and R&D Center, Shuitu, Beibei District, Chongqing, CHN, 400714

Website

http://www.porton.cn

Porton Pharma Solutions Ltd is a China-based external manufacturing supplier of custom drug intermediates and Active Pharmaceutical Ingredients (APIs) to pharmaceutical companies. It is engaged in the process development activities and pilot-scale and commercial-scale manufacturing activities.

Executives

Wang Zhong Neng	Executives
Yu Yong Mei	Executives
Sun Min	Executives
Ji Yao Hui	Executives
Ju Nian Feng	Directors, executives
Tan Jun	Supervisors
Xu Ai Wu	Directors, executives
Guo Yong Qing	Independent director
	Director
	Director
Ceng Hui	Supervisors
Chen Bei	Executives

Porton Pharma Solutions (SZSE:300363) Headlines

No Headlines